Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06284395

Two Schemes Response in Multiple Myeloma

Sponsor: Hospital General de Mexico

View on ClinicalTrials.gov

Summary

Retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the VTD or TD combination.

Official title: Bortezomib, Thalidomide, and Dexamethasone Versus Thalidomide and Dexamethasone for Response Rates in Multiple Myeloma Patients: a Retrospective Study

Key Details

Gender

All

Age Range

18 Years - 90 Years

Study Type

OBSERVATIONAL

Enrollment

83

Start Date

2023-11-20

Completion Date

2024-10-30

Last Updated

2024-10-02

Healthy Volunteers

No

Interventions

DRUG

Bortezomib

Bortezomib 1.3mg/m2 SC on days 1,4, 8,11 to the TD scheme for a total of 6 treatment cycles (14,15) (VTD)

Locations (1)

Hospital General de Mexico Dr. Eduardo Liceaga

Mexico City, Mexico City, Mexico